Yuriko Nagane

Yuriko Nagane

Auto-generated profile, based on publicly available information

Yuriko Nagane

Department of Neurology, Hanamaki General Hospital, Hanamaki

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Neurology Clinical Practice
Verified
Journal Article
Open access
SSShigeaki Suzuki
Shigeaki Suzuki
AUAkiyuki Uzawa
Akiyuki Uzawa
YNYuriko Nagane
Yuriko Nagane
MMMasayuki Masuda
Masayuki Masuda
SKShingo Konno
Shingo Konno
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available in Japan not only for the treatment of anti–acetylcholine receptor–positive (AChR+) but also anti–muscle-specific receptor tyrosine kinase (MuSK+) and seronegative generalized MG. We report details of the use of efgartigimod for generalized MG in clinical practice in Japan. We included patients with generalized MG in the 2021 survey of Japan Myasthenia Gravis Registry (JAMG-R) study group who received an initial cycle of efgartigimod between May and September 2022. We defined “responders” as patients who achieved a score ≥2 points for MG activities of daily living (MG-ADL) in the first treatment cycle. The MG composite and the Revised scale of the 15-item Myasthenia Gravis–Quality of Life scale (MG-QOL15-r) were also evaluated. Of 1,343 JAMG-R patients, 36 (2.7%) started efgartigimod (female 68%, age 53 years). Their serologic profiles were as follows: AChR+, n = 19 (53%); MuSK+, n = 6 (17%); and seronegative, n = 11 (31%). Twenty-six patients (72%) had refractory MG. There were 81 cycles of efgartigimod during the 26-week observation in 34 patients (average, 2.4 cycles). The mean interval between cycles was 5.9 weeks. A continuous 4-weekly infusion of efgartigimod was performed in 65 (80%) of 81 cycles. In the first cycle, the MG-ADL score of the 34 patients decreased significantly from 10.5 ± 4.3 to 6.9 ± 5.1 (p = 0.003). Similarly, the mean MG composite and MG-QOL15-r decreased from 18.4 ± 13.6 to 11.8 ± 9.6 (p = 0.004) and from 19.2 ± 6.3 to 14.2 ± 8.3 (p = 0.007), respectively. Twenty-one (62%) patients were responders. Therapeutic responses were observed in the subsequent cycles. The duration of effectiveness of efgartigimod was varied among the responders; 4 responders had only a single effective cycle. Significant improvement was observed in the MuSK+ patients. Prednisolone dose of 7 patients was reduced. Our examination of the patients' postintervention status revealed that 6 patients achieved minimal manifestations. COVID-19 occurred in 5 patients. We failed to detect clinical or laboratory findings associated with responders. Efgartigimod can be considered for the treatment of patients with generalized MG who do not achieve minimal manifestations, with a broad flexibility of patient selection and treatment schedules.

7 November 2002 in Muscle & Nerve
Verified
Journal Article
Open access
PDF file
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
YNYuriko Nagane
Yuriko Nagane
HYHisashi Yonezawa
Hisashi Yonezawa
DODaiji Obara
Daiji Obara
RKRyushi Kondoh
Ryushi Kondoh
HTHideo Tohgi
Hideo Tohgi
We compared the early effects of FK506 on clinical severity, interleukin-2 (IL-2) production by phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMs), and serum levels of acetylcholine receptor antibodies between myasthenia gravis (MG) patients with elevated (>1250 pg/ml, n = 9) or normal (<1250 pg/mL, n = 10) levels of PBM IL-2 production. Reduction in clinical severity and PBM IL-2 production were significantly greater in the patients with elevated IL-2 production than those with normal PBM IL-2 production in the first month of treatment. Muscle Nerve 27: 245–248, 2003

1 May 2013 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SSShigeaki Suzuki
Shigeaki Suzuki
TNTetsuya Nishimoto
Tetsuya Nishimoto
MKMitsutomo Kohno
Mitsutomo Kohno
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
YNYuriko Nagane
Yuriko Nagane
NSNorihiro Suzuki
Norihiro Suzuki

1 February 1998 in Neuroscience Letters
Verified
Journal Article
Closed access
HTHideo Tohgi
Hideo Tohgi
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
MYMasahiro Yoshimura
Masahiro Yoshimura
YNYuriko Nagane
Yuriko Nagane
MMMasatoshi Mihara
Masatoshi Mihara

1 January 2026 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
YNYuriko Nagane
Yuriko Nagane
HYHuan Yang
Huan Yang
JPJin-Sung Park
Jin-Sung Park
JYJiann-Horng Yeh
Jiann-Horng Yeh
ITIbrahim Turkoz
Ibrahim Turkoz
YMYogeshwar Makanji
Yogeshwar Makanji
Nagane Y, et al. J Clin Neurol. 2026 ;22:e42. https://doi.org/10.3988/jcn.2025.0290

12 February 2013 in Neurology
Verified
Journal Article
Closed access
SSShigeaki Suzuki
Shigeaki Suzuki
HMHiroyuki Murai
Hiroyuki Murai
TITomihiro Imai
Tomihiro Imai
YNYuriko Nagane
Yuriko Nagane
MMMasayuki Masuda
Masayuki Masuda
KUKimiaki Utsugisawa
Kimiaki Utsugisawa